KTTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pasithea Therapeutics Corp (KTTA) is not a strong buy at this moment for a beginner investor with a long-term strategy. The technical indicators suggest a bearish trend, and the company's financial performance shows significant challenges, such as negative net income and declining EPS. While the analyst rating is positive with a high price target, there are no immediate catalysts or trading signals to justify a buy right now. Holding off for better clarity or improvement in fundamentals is recommended.
The stock is currently in a bearish trend with MACD below zero and negatively expanding, RSI indicating oversold conditions at 15.613, and moving averages showing a bearish setup (SMA_200 > SMA_20 > SMA_5). Key support is at 0.704, with resistance levels at 0.783 and 0.862.
Analyst coverage initiated with a Buy rating and a $3 price target, citing a promising pipeline targeting a $20B potential market in orphan and oncology indications.
No recent news or significant trading activity from insiders or hedge funds. Financials show no revenue growth, negative net income, and a significant drop in EPS (-85.71% YoY).
In Q3 2025, the company reported no revenue growth, a net loss of -$3,037,420 (up 1.25% YoY), and a significant drop in EPS to -0.41 (-85.71% YoY). Gross margin remains at 0%.
H.C. Wainwright initiated coverage with a Buy rating and a $3 price target, citing a next-generation MEK inhibitor pipeline with strong potential in the MAPK pathways targeting a $20B market.
